Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression.

@article{Wells2011AbataceptPM,
  title={Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression.},
  author={Alvin F. Wells and Ren{\'e} Westhovens and Diane Moniz Reed and Luciana Fanti and J. Becker and Allison Covucci and Edward Clark Keystone},
  journal={The Journal of rheumatology},
  year={2011},
  volume={38 11},
  pages={2362-8}
}
OBJECTIVE This article reports 1-year clinical outcomes in the subgroup of patients with rheumatoid arthritis in the Abatacept study to Gauge Remission and joint damage progression in methotrexate-naive patients with Early Erosive rheumatoid arthritis (AGREE) who achieved radiographic nonprogression at the end of the double-blind phase. METHODS Patients who achieved radiographic nonprogression (change from baseline in total Sharp score ≤ 0 at 12 months) with abatacept plus methotrexate (MTX… CONTINUE READING
8 Extracted Citations
38 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-8 of 8 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 38 references

Summary of safety in radiographic nonprogressors during 1 year

  • AE Clarke, Y St-Pierre, L Joseph, J Penrod, JT Sibley, M Haga
  • Malignancies
  • 2011

Abatacept demonstrates consistent safety and sustained improvements in efficacy through 4 years of open-label treatment in patients with an inadequate response to anti-TNF therapy [abstract

  • MC Genovese, M Schiff, ME Luggen, M Le Bars, JC Becker, R Aranda
  • Arthritis Rheum
  • 2009

Abatacept demonstrates consistent safety and sustained improvements in efficacy through 5 years of treatment in biologic-naive patients with RA [abstract

  • JM Kremer, AS Russell, P Emery, C Abud-Mendoza, J Szechinski, JC Becker
  • Ann Rheum Dis 2009;68:444
  • 2009

Abatacept increases the proportion of patients who remain free from structural damage progression through 5 years in methotrexate inadequate responders with RA [abstract

  • HK Genant, C Peterfy, R Westhovens, JC Becker, G Vratsanos, X Zhou
  • Ann Rheum Dis 2009;68:440
  • 2009

The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis

  • PM Welsing, AM van Gestel, HL Swinkels, LA Kiemeney, PL. van Riel
  • Arthritis Rheum 2001;44:2009-17
  • 2009

Similar Papers

Loading similar papers…